



Qty. 100 µg/200 µl

Mouse anti-NMDAR1

Catalog No. 32-0500

Lot No.

Mouse anti-NMDA Receptor Subunit 1

FORM

The antibody is supplied as a 200 µl aliquot at a concentration of 0.5 mg/ml in PBS, pH 7.4, containing 0.1% sodium azide. This monoclonal antibody is highly purified from mouse ascites by protein A chromatography.

CLONE: 54.1⁽¹⁾ **ISOTYPE:** IgG_{2a}

IMMUNOGEN

Fusion protein containing sequence from the intracellular loop between transmembrane regions III and IV of NMDAR1.

SPECIFICITY

This antibody specifically recognizes the ~103 kDa NMDAR1 protein. Cross-reactivity with other NMDA receptor proteins has not been observed.

REACTIVITY

This antibody reacts with human, mouse, rat, and monkey NMDAR1.

	ELISA	Immuno-staining (vibratome sections)	Western Blotting
Sample			
Human		+	+
Mouse		+	not tested
Rat		+ ²	+
Monkey		+	+
Immunogen	+		

USAGE⁽¹⁾

Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

ELISA: 0.1-1 µg/ml
Immunostaining²: 5 µg/ml
Western Blotting: 1-5 µg/ml

Reactivity of this antibody in applications other than those named here has not been evaluated.

STORAGE

Store at 2-8°C for up to one month. Store at -20°C for long term storage. Avoid repeated freezing and thawing.

(cont'd)

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI320500

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BACKGROUND

N-methyl-D-Aspartate (NMDA) type receptors are glutamate-activated calcium channels that play central roles in brain function and disease. Activation of NMDA receptors leads to elevations in synaptic calcium levels, initiating a series of calcium dependent signaling events including activation of nitric oxide synthase and stimulation of calcium/calmodulin dependent protein kinase, and MAP kinase cascades. Through these signal transduction pathways, NMDA receptors mediate both synaptic plasticity and learning and memory.

NMDA receptors are composed of multiple subunits. The subunits are thought to co-assemble in different combinations to form functionally distinct NMDA receptors. All receptors contain an NR1 subunit and various numbers of NR2 subunits. NR2b is the major subunit expressed in adult forebrain. NR2 is also a major component of the postsynaptic density in hippocampus and cerebral cortex. The NR1 subunit is encoded by a single gene, which undergoes extensive alternative splicing to generate eight different splice forms. The NR2 subunit class consists of four genes encoding the subunits NR2A-NR2D.

In addition to mediating diverse aspects of synaptic physiology, NMDA receptors also play a major role in neurodegenerative diseases. Overactivity of NMDA receptors is implicated in numerous neurodegenerative processes including stroke, Alzheimer's disease, Huntington's chorea, and amyotrophic lateral sclerosis.

APPLICATION REFERENCE

1. Siegal, et al., *Proc. Natl. Acad. Sci. (USA)* 91:564 (1994).
2. Weiss, S., et al., *Journal of Neuroscience*, 18(5): 1725-1734 (1998).

GENERAL REFERENCE

1. Dingledine R, et al. The glutamate receptor ion channels. *Pharmacol Rev.* 51(1):7-61 (1999).
2. Ziff EB. Recent excitement in the ionotropic glutamate receptor field. *Ann N Y Acad Sci.* 868:465-73 (1999).
3. Sucher, N. J., et al., NMDA receptors: from genes to channels. *Trends Pharmacol. Sci.* 17, 348-355 (1996).

RELATED PRODUCTS

Product	Clone/PAD*	Cat. No.
Rb x NMDA NR1 splice variant N1	--	51-4300
Rb x NMDA NR1 splice variant C1	--	51-4400
Rb x NMDA NR1 splice variant C2	--	51-4500
Rb x NMDA NR1 splice variant C2"	--	51-4600
Rb x NMDA-Receptor 1	2NR2	51-3600
Ms x NMDA-Receptor 1A + 1D	5C4	32-0800
Ms x NMDA-Receptor 2A	A3-2D10	32-0600
Ms x NMDA-Receptor 2B	B3-13B11	32-0700
Rb x NMDA Receptor 2B	2K11	71-8600
Ms x GluR1, 2 and 3	2D8	32-0100
Ms x GluR2 and 4	3A11	32-0200
Ms x GluR3	3B3	32-0400
Rb x mGluR4	ZTS4	51-3100
Ms x Glutamate Transporter EAAC1	35-A9	32-1000
Ms x α -CaM Kinase II	CB α -2	13-7300
Ms x β -CaM Kinase II	CB β -1	13-9800
Rb x Glycine Receptor	--	51-5300
Ms x Nitrotyrosine	HM11	32-1900
Rb x Synapsin-1	--	51-5200
Rb x Synaptophysin	Z66	18-0130
Ms x Tyrosine Hydroxylase	1hy1	32-2100
Ms x Ubiquitin	Ubi-1	13-1600

*Polyclonal Antibody Designation

Conjugate	ZyMAX™ Goat x Rabbit IgG (H+L)	ZyMAX™ Goat x Mouse IgG (H+L)
Unconjugated	81-6100	81-6500
FITC	81-6111	81-6511
TRITC	81-6114	81-6514
Cy™3	81-6115	81-6515
Cy™5	81-6116	81-6516
HRP	81-6120	81-6520
AP	81-6122	81-6522
Biotin	81-6140	81-6540

Zymed® and ZyMAX™ are trademarks of Zymed Laboratories Inc. Cy™ is a trademark of Amersham Life Sciences, Inc. Sepharose® is a registered trademark of Pharmacia LKB.

For Research Use Only

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI320500

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.